KR20110038375A - Pharmaceutical composition comprising extract of aster koraiensis for alalgesic - Google Patents
Pharmaceutical composition comprising extract of aster koraiensis for alalgesic Download PDFInfo
- Publication number
- KR20110038375A KR20110038375A KR1020090095639A KR20090095639A KR20110038375A KR 20110038375 A KR20110038375 A KR 20110038375A KR 1020090095639 A KR1020090095639 A KR 1020090095639A KR 20090095639 A KR20090095639 A KR 20090095639A KR 20110038375 A KR20110038375 A KR 20110038375A
- Authority
- KR
- South Korea
- Prior art keywords
- pain
- extract
- composition
- analgesic
- bee
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 42
- 241000673753 Aster koraiensis Species 0.000 title claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 5
- 208000002193 Pain Diseases 0.000 claims abstract description 31
- 230000036407 pain Effects 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000013305 food Nutrition 0.000 claims abstract 5
- 239000000287 crude extract Substances 0.000 claims abstract 3
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 2
- 230000000202 analgesic effect Effects 0.000 claims description 26
- 230000003444 anaesthetic effect Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 6
- 230000003187 abdominal effect Effects 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 230000003119 painkilling effect Effects 0.000 abstract 4
- 241000699670 Mus sp. Species 0.000 description 20
- 238000012360 testing method Methods 0.000 description 19
- 241000254173 Coleoptera Species 0.000 description 14
- 241000272878 Apodiformes Species 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 8
- 229930014626 natural product Natural products 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102100024304 Protachykinin-1 Human genes 0.000 description 5
- 101800003906 Substance P Proteins 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229960005181 morphine Drugs 0.000 description 4
- 230000003533 narcotic effect Effects 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000929 nociceptor Anatomy 0.000 description 2
- 108091008700 nociceptors Proteins 0.000 description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241001374849 Liparis atlanticus Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010072005 Spinal pain Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000005298 gastrointestinal allergy Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- RZSCFTDHFNHMOR-UHFFFAOYSA-N n-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]pyridine-3-carboxamide;1,1-dimethyl-3-(4-propan-2-ylphenyl)urea Chemical compound CC(C)C1=CC=C(NC(=O)N(C)C)C=C1.FC1=CC(F)=CC=C1NC(=O)C1=CC=CN=C1OC1=CC=CC(C(F)(F)F)=C1 RZSCFTDHFNHMOR-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229940020463 prialt Drugs 0.000 description 1
- 230000026416 response to pain Effects 0.000 description 1
- 239000003711 snail venom Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940072651 tylenol Drugs 0.000 description 1
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
현재, 진통제로는 아스피린이나 타이레놀 등의 소염진통제가 주류를 이루며, 심한 통증의 경우 모르핀 약물들이 대부분 사용되고 있다. 최근 새로운 통증억제제를 개발하고 있는데, 외국의. 경우, 통증 치료제 전문 개발사 자벨린 파마슈티컬스(Javelin Pharmaceuticals) 비강내 모르핀 분무제 릴로민(Rylomine)이 후기 2상 임상에서 중등도에서 중증 수술후 통증의 치료에 정맥주사 모르핀과 대등한 진통효과를 나타내는 뿌리는 마약성 진통제를 개발하였으며, 중국에서는 상하이 싱롱 바오테크 제약회사에서 위와 이오테크 제약회사에서 위와장(腸), 유방, 폐, 신장과 관련된 암으로 인한 통증에 효능이 있는 신약' 아킬레스'를 개발하였다. 또한, 바다 달팽이 독에서 추출한 새로운 진통제 '프라이얼트(Prialt)를 아일랜드 제약회사인 이랜(Elan)이 개발한 진통제로 영국에서 첫 시판됐었다.Currently, as analgesics, anti-inflammatory drugs such as aspirin and tylenol are the mainstream, and in case of severe pain, morphine drugs are mostly used. Recently, a new pain inhibitor is being developed. In this case, the drug developer, Javelin Pharmaceuticals' intranasal morphine spray lylomine, has a pain relief effect comparable to that of intravenous morphine in the treatment of moderate to severe postoperative pain in
국내에서는 캡사이신 길항물질을 개발하여 2004년 2월에 독일의 다국적 제약업체인 슈바르쯔 파마社가 이의 가치를 인정, 공동연구 및 라이선스 계약을 체결하였다. 벌개미취 꽃을 이용하여 통증제로 개발하거나 시도된 바는 없다.In Korea, Germany developed a capsaicin antagonist, and in February 2004, Schwarz Pharma, a German multinational pharmaceutical company, recognized the value and signed a joint research and licensing agreement. There have been no attempts to develop or attempt pain relief using bee-flavored flowers.
만성 악성 종양성 통증은 물론 사회가 고령화됨에 따라 퇴행성 관절염, 요통 관련 질환 환자는 매년 증가 추세에 있으나 모르핀과 같은 기존의 아편제제는 일반인에게 마약작용으로 인하여 사용에 제한이 있고, 통증자체가 질병으로 여겨지며 이에 대한 관심이 어느 때보다 높고 확산되고 있어 통증완화제의 수요는 향후 훨씬 더 늘 것으로 예상되며 기존의 진통제에 반응하지 않는 통증에 대한 진통제 개발이 크게 요구되는 시점이며 기존의 마약성 및 비마약성 진통제들에 반응하지 않는 통증환자가 많이 보고될 뿐만 아니라 진통효과가 상대적으로 큰 것으로 알려진 기존의 아편유사제제 등이 마약성 및 심각한 부작용들로 인해 일반 환자가 편하게 사용할 수 없는 실정이므로 신청기술인 부작용이 없는 새로운 진통억제 효능이 있는 천연자원을 개발하고자 한다.As the society ages, as well as chronic malignant neoplastic pain, patients with degenerative arthritis and low back pain are increasing every year. However, existing opiates such as morphine have limited use due to narcotic action and the pain itself is a disease. The demand for pain relievers is expected to be much higher in the future, and the development of painkillers for pain that does not respond to existing painkillers is in high demand and existing narcotic and non-narcotic painkillers There are many reports of pain patients who do not respond to them, and existing opioids, which are known to have relatively high analgesic effects, cannot be used conveniently by general patients due to narcotic and serious side effects. Develop natural resources with new analgesic effects I would like to.
본 발명은 우수한 진통효과를 나타내는 벌개미취 꽃을 추출한 후, 다양한 통증에 대한 여러 가지 지표에 대한 테스트를 실시하여 우수한 진통억제 효과를 나타내는 벌개취 꽃 추출물을 포함하는 진통제 조성물에 관한 것이다. The present invention relates to an analgesic composition comprising a bee-flavored flower extract that exhibits an excellent analgesic inhibitory effect by extracting a bee-flavored flower that exhibits excellent analgesic effect and then testing various indicators for various pains.
현재까지 진통제로는 아세트아미노펜, 아스피린 등이 사용되어 왔으나, 이들은 성인에게 1일 약 1g 내지 4g의 고용량으로 투여되어야 하고 이로 인해 위장장애, 알레르기, 간독성 등의 부작용이 있다. 이에 따라 부작용이 없이 저용량으로도 진통 효과가 우수한 새로운 진통제의 개발이 절실히 요구되고 있다.To date, as analgesics, acetaminophen, aspirin, etc. have been used, but they should be administered to adults at high doses of about 1 g to 4 g per day, which causes side effects such as gastrointestinal disorders, allergies, and liver toxicity. Accordingly, there is an urgent need for the development of new analgesic agents having excellent analgesic effects even at low doses without side effects.
벌개미취(Aster koraiensis Nakai)는 학명에서 보듯 우리 한국의 특산식물로서 고장에 따라서는 고려 쑥부쟁이라 부르기도하며 국화과에 속하는 여러해살이 풀꽃으로 7월말경부터 꽃대를 자라게 하는데 8월중순까지 자라서 60~90센치미터 혹은 1 미터까지도 자라게 우리나라 남한 어느지역에서나 흔하게 볼 수가 있고 특히, 강원도지방에서 많은 개체가 자라고있다As the name suggests, Aster koraiensis Nakai is a Korean native plant, sometimes called Goryeo wormwood, and it is a perennial plant belonging to the Asteraceae family. It grows from the end of July until the end of July. It grows up to 1 meter or 1 meter and is common in any part of South Korea. Especially, many individuals grow in Gangwon Province.
그러나 지금까지 벌개미취 꽃 추출물의 진통효능에 대한 연구가 보고 된 바 없다.However, there have been no studies on the analgesic efficacy of bee-flavored flower extracts.
본 발명의 목적은 벌개미취 꽃 추출물 혹은 이를 포함하는 진통효과가 우수한 진통제 조성물을 제공하는데 있다.It is an object of the present invention to provide an analgesic composition having excellent analgesic effect including bee anesthetized flower extract or the same.
벌개미취 꽃 추출물을 이용한 라이딩(writhing) 억제 시험, 포르말린 시험, 물질 P 통증 시험, 꼬리 움직임 시험(tail-flick test)를 통하여 진통효과를 측정 규명한다.The analgesic effect is measured through the riding inhibition test, formalin test, substance P pain test, and tail-flick test using bee-flavored flower extracts.
본 발명은 진통제 조성물에 과한 것으로 벌개미취 꽃 추출물을 이용한 진통효과를 얻는 것을 그 특징으로 하며 이는 천연물에서 유래한 진통제 조성물이라는 측면에서 그 의의가 있으며 이를 적극적으로 활용할 경우 다양한 질병에 대한 진통제 조성물로서 널리 활용될 수 있으며 나아가 국민 건강에 기여 할 수 있다.The present invention is characterized by obtaining an analgesic effect using a bee-flavored flower extract, which is excessive in the analgesic composition, which is meaningful in terms of analgesic composition derived from natural products and widely used as an analgesic composition for various diseases. It can also contribute to national health.
본 발명의 벌개미취 추출물은, 건조된 벌개미취 꽃의 무게의 10배의 메탄올을 가하고 수용액상에서 70에서 3시간 동안 추출한 다음 이를 여과하여 추출액을 얻는다. 추출하는 과정을 2회 반복한다. 얻어진 추출액을 40 이하에서 감압 농축한 후 이를 동결 건조하여 분말상의 추출물을 얻는다. Beetle odor extract of the present invention is added to
본 발명은 다음의 실시 예에 의거하여 더욱 상세히 설명되나, 본 발명이 이에 의해 제한되지는 않는다.The present invention is described in more detail based on the following examples, but the present invention is not limited thereto.
시료제조예 : 본 발명의 벌개미취 추출물은, 건조된 벌개미취 꽃의 무게의 10배의 에탄올을 가하고 수용액상에서 70에서 3시간 동안 추출한 다음 이를 여과하여 추출액을 얻는다. 추출하는 과정을 2회 반복한다. 얻어진 추출액을 40 이하에서 감압 농축한 후 이를 동결 건조하여 분말상의 추출물을 얻는다. Sample Preparation Example : The bee anesthetist extract of the present invention was added with
본 발명은 다음의 실시 예에 의거하여 더욱 상세히 설명되나, 본 발명이 이에 의해 제한되지는 않는다.The present invention is described in more detail based on the following examples, but the present invention is not limited thereto.
실시예Example 1: 벌개미취 꽃 추출물의 1: Of Beetle Anesthetic Flower Extract 라이딩Riding (( writhingwrithing ) 억제 시험Suppression test
제조예 에서 얻은 벌개미취 꽃 추출물을 4주령 ICR 생쥐(체중 약 25g)에게 각각 200 /의 양으로 경구투여 하였다. 이어서 생쥐의 복강에 1 % 초산 0.25 를 투여한 다음 30 분 동안 라이딩 반응(writhing response)을 조사하였다. 이때 대조군으로서 천연물(벌개미취)이 투여되지 않은 생쥐를 사용하여 동일하게 시험하였다.Beetle anesthetized flower extracts obtained in the preparations were orally administered to 4 week old ICR mice (about 25 g body weight) in an amount of 200 /. Subsequently, 0.25% of 1% acetic acid was administered to the abdominal cavity of the mice, and the riding response was examined for 30 minutes. At this time, the same test was performed using mice that were not administered natural products (beetle odor) as a control.
도 1은 벌개미취 꽃 추출물의 투여에 따른 라이딩 회수를 나타내는 그래프이다. 도 1에서 보듯이, 벌개미취 꽃 추출물은 초산에 의한 라이딩 반응을 억제한다.1 is a graph showing the number of riding according to the administration of bee anesthesia flower extract. As shown in FIG. 1, the bee sting flower extract inhibits the riding reaction by acetic acid.
실시예Example 2: 벌개미취 꽃 추출물의 포르말린 시험 2: Formalin Test of Beetle Anemone Flower Extract
제조예 에서 얻은 벌개미취 꽃 추출물을 4주령 ICR 생쥐(체중 약 25g)에게 각각 200 mg/kg의 양으로 경구투여 하였다. 이 후 30 분이 경과한 때에, 각각의 생쥐의 뒷 발바닥에 5% 포르말린 수용액을 투여한 후, 처음 5분 동안의 제 1 기 및, 20 내지 40 분의 동안의 제 2 기에 생쥐가 발바닥을 핥거나 흔드는 등의 통증 반응을 보이는 시간을 측정하였다. 이때 대조군으로서 벌개미취 꽃 추출물이 투여되지 않은 생쥐를 사용하여 동일하게 시험하였다.Beetle anesthetized flower extract obtained in Preparation Example was orally administered to 4 week old ICR mice (about 25 g body weight) in an amount of 200 mg / kg. At the end of 30 minutes, 5% formalin aqueous solution was administered to the rear paws of each mouse, and then the mice licked the paws in the first stage for the first 5 minutes and the second stage for 20 to 40 minutes. The time of showing pain response of shaking back was measured. At this time, the test was performed in the same manner as the control mice using no bee anesthetized flower extract.
도 2는 벌개미취 꽃 추출물의 투여에 따라 생쥐가 각각 제 1 기 및 제 2 기에 보인 통증 기간(초)을 나타낸다. 도2에서 보듯이, 벌개미취 꽃 추출물은 포르말린에 의한 제 2 기의 통증 반응을 억제한다.Figure 2 shows the pain period (seconds) seen in the first and second stages of the mice, respectively, according to the administration of the hummingbird flower extract. As shown in Fig. 2, the bee-bloomed flower extract inhibits the second stage pain response by formalin.
실시예Example 3: 천연물(벌개미취)의 물질 P 통증 시험 3: Substance P Pain Test of Natural Products
제조예 에서 얻은 천연물(벌개미취)을 4주령 ICR 생쥐(체중 약 25g)에게 각각 200 /의 양으로 경구투여 하였다. 이 후 30 분이 경과한 때에, 각각의 생쥐의 척수강(intrathecal)에 물질 P(Substance P)를 0.7 의 양으로 투여한 후, 30 분 동안 생쥐가 발바닥을 핥거나 흔드는 등의 통증 반응을 보이는 시간을 측정하였다. 이때 대조군으로서 천연물(벌개미취)이 투여되지 않은 생쥐를 사용하여 동일하게 시험하였다.The natural product (beetle odor) obtained in Preparation Example was orally administered to 4 week old ICR mice (about 25 g body weight) in an amount of 200 /. After 30 minutes, the amount of substance P (Substance P) was administered to the intrathecal of each mouse in an amount of 0.7, and the mice had pain reactions such as licking or shaking the soles for 30 minutes. Measured. At this time, the same test was performed using mice that were not administered natural products (beetle odor) as a control.
도 3은 천연물(벌개미취)의 투여에 따른 생쥐의 통증 기간(초)을 나타낸다. 도 3에서 보듯이, 천연물(벌개미취)은 물질 P에 의한 통증 반응을 억제한다.Figure 3 shows the duration of pain (seconds) of mice following the administration of natural products (beetle anesthesia). As shown in Fig. 3, the natural product (beetle odor) suppresses the pain response by the substance P.
실시예Example 4: 벌개미취 꽃 추출물의 꼬리 움직임 시험( 4: Tail Movement Test of Beetle Anemone Flower Extract tailtail -- flickflick testtest ))
제조예 에서 얻은 벌개미취 꽃 추출물을 4주령 ICR 생쥐(체중 약 25g)에게 각각 200 /의 양으로 경구투여 하였다. 이어서, 각각의 생쥐의 꼬리에 빛(radient heat)을 쪼인 후 이러한 작열성 동통 수용기(thermal nociceptor) 자극으로 인한 통증으로 꼬리 움직임 반응을 보이는 시간을 측정하여 진통 기간(초)을 결정하였다. 이 검사법은 척수동통 회로에 대한 약물의 진통 효과를 확인해준다. 이 때 대조군으로서 벌개물취 꽃 추출물이 투여되지 않은 생쥐를 사용하여 동일하게 시험하였다.Beetle anesthetized flower extracts obtained in the preparations were orally administered to 4 week old ICR mice (about 25 g body weight) in an amount of 200 /. Subsequently, the duration of analgesia (seconds) was determined by measuring the time at which the tail movement response was caused by pain of the thermal nociceptor stimulation after radiating heat to the tail of each mouse. This test confirms the analgesic effect of the drug on the spinal pain circuit. In this case, the same test was performed using mice not subjected to the bee squirt flower extract as a control.
도 4는 200 mg/kg의 벌개미취 꽃 추출물이 투여된 생쥐에 빛을 쪼인 후 시간 경과에 따른 진통 기간(초)을 나타내며, 도 4는 벌개미취 꽃 추출물의 투여 용량에 따른 진통 기간(초)을 나타낸다. 도 4에서 보듯이, 벌개미취 꽃 추출물은 빛을 쪼인 후 꼬리 움직임 반응을 억제한다.Figure 4 shows the analgesic period (seconds) over time after light to the mice administered the 200 mg / kg hummingbird anesthetic flower extract, Figure 4 shows the analgesic period (seconds) according to the administration dose of the hummingbird anesthetic flower extract. . As shown in Figure 4, the hummingbird flower extract inhibits the tail movement response after shining light.
실시예Example 5: 벌개미취 꽃 추출물의 뜨거운 바닥 시험( 5: hot bottom test of bee and anesthetic flower extract ( HotHot -- plateplate testtest ))
제조예 에서 얻은 벌개미취 꽃 추출물을 4주령 ICR 생쥐(체중 약 25g)에게 각각 200 /의 양으로 경구투여 하였다. 이어서, 각각의 생쥐를 55도씨의 뜨거운 바닥에 올려 놓은 후 이러한 작열성 동통 수용기(thermal nociceptor) 자극으로 인한 통증으로 발바닥 움직임 반응을 보이는 시간을 측정하여 진통 기간(초)을 결정하였다. 이 검사법은 말초에서 중추로의 회로에 대한 약물의 진통 효과를 확인해준다. 이 때 대조군으로서 천연물(벌개미취)이 투여되지 않은 생쥐를 사용하여 동일하게 시험하였다.Beetle anesthetized flower extracts obtained in the preparations were orally administered to 4 week old ICR mice (about 25 g body weight) in an amount of 200 /. The duration of labor (seconds) was then determined by placing each mouse on a hot floor at 55 degrees C and then measuring the time for the plantar movement response to pain due to this thermal nociceptor stimulus. This test confirms the analgesic effect of the drug on the peripheral to central circuit. At this time, the same test was conducted using mice that were not administered natural products (beetle anesthesia) as a control.
도 5는 200 mg/kg의 벌개미취 꽃 추출물이 투여된 생쥐를 뜨거운 바닥에 올려 놓은 후 시간 경과에 따른 진통 기간(초)을 나타낸다. 도 5에서 보듯이, 벌개미취 꽃 추출물은 뜨거운 바닥에서 견디는 진통 시간을 증가시킨다.Figure 5 shows the duration of labor (seconds) over time after placing a mouse administered with 200 mg / kg hummingbird flower extract on a hot floor. As shown in Figure 5, the hummingbird flower extract increases the analgesic time to endure on the hot bottom.
도1은 벌개미취 꽃 추출물의 투여에 따른 라이딩(writhing) 억제효과를 나타내는 그래프이다.Figure 1 is a graph showing the inhibitory effect of riding (writhing) according to the administration of bee anesthesia flower extract.
도2는 벌개미취 꽃 추출물의 투여에 따라 생쥐가 각각 제 1 기 및 제 2 기에 보인 통증 기간(초)을 나타내는 그래프이다. Figure 2 is a graph showing the pain period (seconds) seen in the first and second stages of the mice, respectively, according to the administration of the hummingbird flower extract.
도3은 벌개미취 꽃 추출물의 투여에 따른 생쥐의 통증 기간(초)을 나타내는 그래프이다.Figure 3 is a graph showing the pain period (seconds) of the mice according to the administration of bee anesthesia flower extract.
도4는 200 /의 벌개미취 꽃 추출물이 투여된 생쥐에 빛을 쪼인 후 시간 경과에 따른 진통 기간(초)을 나타내는 그래프이다.Figure 4 is a graph showing the analgesic period (seconds) over time after light to the mice administered the hummingbird anesthetic flower extract of 200 /.
도5는 200 /의 벌개미취 꽃 추출물이 투여된 생쥐를 뜨거운 바닥(hot plate)에 올려 놓은 후 시간 경과에 따른 진통 기간(초)을 나타내는 그래프이다.Figure 5 is a graph showing the duration of labor (seconds) over time after placing the mice with the honeycomb flower extract of 200 / on a hot plate (hot plate).
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090095639A KR20110038375A (en) | 2009-10-08 | 2009-10-08 | Pharmaceutical composition comprising extract of aster koraiensis for alalgesic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090095639A KR20110038375A (en) | 2009-10-08 | 2009-10-08 | Pharmaceutical composition comprising extract of aster koraiensis for alalgesic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20110038375A true KR20110038375A (en) | 2011-04-14 |
Family
ID=44045451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020090095639A KR20110038375A (en) | 2009-10-08 | 2009-10-08 | Pharmaceutical composition comprising extract of aster koraiensis for alalgesic |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20110038375A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104780928A (en) * | 2012-12-18 | 2015-07-15 | 财团法人医药工业技术发展中心 | Use of tatarian aster extract in preparing medicament for treating pain |
| KR20180006612A (en) * | 2016-07-08 | 2018-01-18 | 한국 한의학 연구원 | Compositions for preventing or treating diabetes mellitus comprising extract of Aster koraiensis or fraction thereof |
| WO2019098615A1 (en) * | 2017-11-17 | 2019-05-23 | 한국한의학연구원 | Composition containing aster k oraiensis extract or fraction thereof for prevention or treatment of dry eye |
-
2009
- 2009-10-08 KR KR1020090095639A patent/KR20110038375A/en not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104780928A (en) * | 2012-12-18 | 2015-07-15 | 财团法人医药工业技术发展中心 | Use of tatarian aster extract in preparing medicament for treating pain |
| KR20180006612A (en) * | 2016-07-08 | 2018-01-18 | 한국 한의학 연구원 | Compositions for preventing or treating diabetes mellitus comprising extract of Aster koraiensis or fraction thereof |
| WO2019098615A1 (en) * | 2017-11-17 | 2019-05-23 | 한국한의학연구원 | Composition containing aster k oraiensis extract or fraction thereof for prevention or treatment of dry eye |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI643631B (en) | Compositions and methods for joint health | |
| Hiruma-Lima et al. | The juice of fresh leaves of Boerhaavia diffusa L.(Nyctaginaceae) markedly reduces pain in mice | |
| Sun et al. | Evaluation of Analgesic and Anti‐Inflammatory Activities of Water Extract of Galla Chinensis In Vivo Models | |
| González-Trujano et al. | Identification of some bioactive metabolites and inhibitory receptors in the antinociceptive activity of Tagetes lucida Cav. | |
| Montrucchio et al. | Antinociceptive effects of a chloroform extract and the alkaloid dicentrine isolated from fruits of Ocotea puberula | |
| Barua et al. | Antinociceptive activity of methanolic extract of leaves of Achyranthes aspera Linn.(Amaranthaceae) in animal models of nociception | |
| KR20110038375A (en) | Pharmaceutical composition comprising extract of aster koraiensis for alalgesic | |
| CN104274502B (en) | A kind of extracting method of the efficient antiinflammatory action compound of euscaphis konishii, product | |
| Zakaria et al. | The influences of temperature and naloxone on the antinociceptive activity of Corchorus olitorius L. in mice | |
| KR101223662B1 (en) | Composition for alalgesic comprising an extract of agrimonia | |
| KR101132040B1 (en) | Composition for alalgesic or neurophatic pain comprising extract of symplocos chinensis for. pilosa or its leaf | |
| Akhter et al. | Investigation of in vivo analgesic and anti-inflammatory activities of methanol extracts of Phyllanthus reticulatus and Mimosa pigra | |
| CN102579559B (en) | Bauhinia championii ethyl acetate extract, n-butyl alcohol extract, and preparation methods and applications thereof | |
| CN101978963B (en) | Annonaceous acetogenin extract, preparation method thereof and use thereof in cancer resistance and relief of cancerous pain | |
| Tesema et al. | In vivo analgesic and antipyretic activities of N-Butanol and water fractions of Ocimum sauve | |
| CN101172124B (en) | Novel uses of pennycress, pharmaceutical composition containing the pennycress and preparation method thereof | |
| CN101549039B (en) | Application of schisandra fruit or related monomeric compound thereof for preventing or curing fatty liver | |
| KR20110038386A (en) | Pharmaceutical composition comprising extract of pulsatilla koreana for alalgesic | |
| Ameer et al. | Vasorelaxant properties of Loranthus ferrugineus Roxb. methanolic extract | |
| KR101938933B1 (en) | Compositions for alleviating, preventing or treating inflammatory Pain comprising extract from Chaenomeles sinensis and Glycyrrhizae and Aralia elata | |
| KR100715939B1 (en) | Therapeutic Agent for Narcotics Addiction | |
| CN104435293B (en) | Application of the Kadsura heteroclita total triterpene ethanol extract in preparation anti-arthritic drugs | |
| CN101385768B (en) | Application of Loitered sheep root eluate in preparing drugs of chronic glomerulonephritis treatment | |
| KR20110038381A (en) | Pharmaceutical composition comprising extract of viola tricolor for alalgesic | |
| CN104739949A (en) | Composition for treating Parkinson disease and preparation method of composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |